(NASDAQ: GLTO) Galecto's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.13%.
Galecto's earnings in 2024 is -$25,426,000.On average, 1 Wall Street analyst forecast GLTO's earnings for 2024 to be -$20,347,650, with the lowest GLTO earnings forecast at -$20,347,650, and the highest GLTO earnings forecast at -$20,347,650. On average, 1 Wall Street analyst forecast GLTO's earnings for 2025 to be -$29,300,616, with the lowest GLTO earnings forecast at -$29,300,616, and the highest GLTO earnings forecast at -$29,300,616.
In 2026, GLTO is forecast to generate -$47,206,548 in earnings, with the lowest earnings forecast at -$47,206,548 and the highest earnings forecast at -$47,206,548.